IL6 and neoplasm: Studies in neuroblastoma have demonstrated that tumor cells induce suppressive macrophage populations, which inhibit effector NK cells via secretion of IL-6 and TGF-β and thus dampen the efficiency of anti-GD2-targeted immunotherapy [19,101].